Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years
Mesenchymal chondrosarcoma(MCS) is a rare high-grade variant of chondrosarcoma. Consensus has not been reached on its optimal management. Resection with wide margins is usually recommended, but the effect of margins has been demonstrated by little positive evidence. Moreover, the effectiveness of ad...
Gespeichert in:
| Veröffentlicht in: | PloS one 2015-04, Vol.10 (4), p.e0122216-e0122216 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0122216 |
|---|---|
| container_issue | 4 |
| container_start_page | e0122216 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Xu, Jie Li, Dasen Xie, Lu Tang, Shun Guo, Wei |
| description | Mesenchymal chondrosarcoma(MCS) is a rare high-grade variant of chondrosarcoma. Consensus has not been reached on its optimal management. Resection with wide margins is usually recommended, but the effect of margins has been demonstrated by little positive evidence. Moreover, the effectiveness of adjuvant chemo- and/or radiotherapy remains controversial.
To describe the clinical characteristics and outcomes of MCS of bone and soft tissue, to assess the efficacies of surgery, chemotherapy and radiation, and finally to deliver a more appropriate therapy.
We reviewed EMBASE-, MEDLINE-, Cochrane-, Ovid- and PubMed-based to find out all cases of MCS of bone and soft tissue described between April 1994 and April 2014. Description of treatment and regular follow-up was required for each study. Language was restricted to English and Chinese. Issues of age, gender, location, metastasis, and treatment were all evaluated for each case. Kaplan-Meier Method and Cox Proportional Hazard Regression Model were used in the survival analysis.
From the 630 identified publications, 18 meeting the inclusion criteria were selected, involving a total of 107 patients. Based on these data, the 5-, 10-and 20-year overall survival are 55.0%, 43.5% and 15.7% respectively. The 5-, 10-, 20- year event-free survival rates are 45.0%, 27.2% and 8.1%, respectively. Treatment without surgery is associated with poorer overall survival and event-free survival. Negative surgical margins could significantly bring down the local-recurrence rate and are associated with a higher event-free survival rate. Chemotherapy regime based on anthracyclines does not benefit the overall survival. The addition of radiation therapy is not significantly associated with the overall or event-free survival. However, we recommend radiation as the salvage therapy for patients with positive margin so as to achieve better local control.
This review shows that surgery is essential in the management of MCS of bone and soft tissue. Appropriate adjuvant therapy may reduce local recurrence, but cannot benefit the overall survival. |
| doi_str_mv | 10.1371/journal.pone.0122216 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1671014143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A429778510</galeid><doaj_id>oai_doaj_org_article_114763b3feea4da8a2fbd6bf0f1dd709</doaj_id><sourcerecordid>A429778510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-69dc1c3d86c56ef381fbf123fd1694e725c3e7d303474c2d274719cb8f48843e3</originalsourceid><addsrcrecordid>eNqNk0tv1DAQxyMEoqXwDRBYQkJw2MWvxAkHpKrisVJRJV5Xy7HHu1kl8dZ2Cvvt8e6m1Qb1gHywPf7NfzxjT5Y9J3hOmCDv1m7wvWrnG9fDHBNKKSkeZKekYnRWUMweHq1PsichrDHOWVkUj7MTmpe8orQ4zdqvEKDXq22nWqRXrjfeBeW16xRyFtVJHKneoOBsRLEJYYD3SKGwDRE6FRuNPNw08HsHEyzQJtmgjwE1PYorSPsQEcVoC8qHp9kjq9oAz8b5LPv56eOPiy-zy6vPi4vzy5kWeRlnRWU00cyUhc4LsKwktraEMmtIUXEQNNcMhGGYccE1NVRwQSpdl5aXJWfAzrKXB91N64IcCxUkKQTBhBPOErE4EMaptdz4plN-K51q5N7g_FIqn7JrQRLCRcFqZgEUN6pU1NamqC22xBiBq6T1YYw21B0YndL3qp2ITk_6ZiWX7kZyVpa5oEngzSjg3fUAIcquCRraVvXghv29Ka4I3sd69Q96f3YjtVQpgaa3LsXVO1F5zmklRJkTnKj5PVQaBrpGp4e3TbJPHN5OHBIT4U9cqiEEufj-7f_Zq19T9vURuwLVxlVw7RAb14cpyA-gTp80eLB3RSZY7prithpy1xRybIrk9uL4ge6cbruA_QVaFAaE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1671014143</pqid></control><display><type>article</type><title>Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Xu, Jie ; Li, Dasen ; Xie, Lu ; Tang, Shun ; Guo, Wei</creator><contributor>Loeb, David M</contributor><creatorcontrib>Xu, Jie ; Li, Dasen ; Xie, Lu ; Tang, Shun ; Guo, Wei ; Loeb, David M</creatorcontrib><description>Mesenchymal chondrosarcoma(MCS) is a rare high-grade variant of chondrosarcoma. Consensus has not been reached on its optimal management. Resection with wide margins is usually recommended, but the effect of margins has been demonstrated by little positive evidence. Moreover, the effectiveness of adjuvant chemo- and/or radiotherapy remains controversial.
To describe the clinical characteristics and outcomes of MCS of bone and soft tissue, to assess the efficacies of surgery, chemotherapy and radiation, and finally to deliver a more appropriate therapy.
We reviewed EMBASE-, MEDLINE-, Cochrane-, Ovid- and PubMed-based to find out all cases of MCS of bone and soft tissue described between April 1994 and April 2014. Description of treatment and regular follow-up was required for each study. Language was restricted to English and Chinese. Issues of age, gender, location, metastasis, and treatment were all evaluated for each case. Kaplan-Meier Method and Cox Proportional Hazard Regression Model were used in the survival analysis.
From the 630 identified publications, 18 meeting the inclusion criteria were selected, involving a total of 107 patients. Based on these data, the 5-, 10-and 20-year overall survival are 55.0%, 43.5% and 15.7% respectively. The 5-, 10-, 20- year event-free survival rates are 45.0%, 27.2% and 8.1%, respectively. Treatment without surgery is associated with poorer overall survival and event-free survival. Negative surgical margins could significantly bring down the local-recurrence rate and are associated with a higher event-free survival rate. Chemotherapy regime based on anthracyclines does not benefit the overall survival. The addition of radiation therapy is not significantly associated with the overall or event-free survival. However, we recommend radiation as the salvage therapy for patients with positive margin so as to achieve better local control.
This review shows that surgery is essential in the management of MCS of bone and soft tissue. Appropriate adjuvant therapy may reduce local recurrence, but cannot benefit the overall survival.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0122216</identifier><identifier>PMID: 25849226</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Anthracycline ; Bone cancer ; Bone Neoplasms - drug therapy ; Bone Neoplasms - radiotherapy ; Bone Neoplasms - surgery ; Bone surgery ; Bone tumors ; Cancer metastasis ; Chemotherapy ; Chondrosarcoma ; Chondrosarcoma, Mesenchymal - drug therapy ; Chondrosarcoma, Mesenchymal - radiotherapy ; Chondrosarcoma, Mesenchymal - surgery ; Humans ; Mesenchyme ; Metastases ; Patients ; Quality ; Radiation ; Radiation (Physics) ; Radiation therapy ; Regression analysis ; Regression models ; Salvage ; Soft Tissue Neoplasms - drug therapy ; Soft Tissue Neoplasms - radiotherapy ; Soft Tissue Neoplasms - surgery ; Stem cells ; Surgery ; Survival ; Treatment Outcome</subject><ispartof>PloS one, 2015-04, Vol.10 (4), p.e0122216-e0122216</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Xu et al 2015 Xu et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-69dc1c3d86c56ef381fbf123fd1694e725c3e7d303474c2d274719cb8f48843e3</citedby><cites>FETCH-LOGICAL-c758t-69dc1c3d86c56ef381fbf123fd1694e725c3e7d303474c2d274719cb8f48843e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388572/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388572/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,2914,23846,27903,27904,53770,53772,79347,79348</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25849226$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Loeb, David M</contributor><creatorcontrib>Xu, Jie</creatorcontrib><creatorcontrib>Li, Dasen</creatorcontrib><creatorcontrib>Xie, Lu</creatorcontrib><creatorcontrib>Tang, Shun</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><title>Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Mesenchymal chondrosarcoma(MCS) is a rare high-grade variant of chondrosarcoma. Consensus has not been reached on its optimal management. Resection with wide margins is usually recommended, but the effect of margins has been demonstrated by little positive evidence. Moreover, the effectiveness of adjuvant chemo- and/or radiotherapy remains controversial.
To describe the clinical characteristics and outcomes of MCS of bone and soft tissue, to assess the efficacies of surgery, chemotherapy and radiation, and finally to deliver a more appropriate therapy.
We reviewed EMBASE-, MEDLINE-, Cochrane-, Ovid- and PubMed-based to find out all cases of MCS of bone and soft tissue described between April 1994 and April 2014. Description of treatment and regular follow-up was required for each study. Language was restricted to English and Chinese. Issues of age, gender, location, metastasis, and treatment were all evaluated for each case. Kaplan-Meier Method and Cox Proportional Hazard Regression Model were used in the survival analysis.
From the 630 identified publications, 18 meeting the inclusion criteria were selected, involving a total of 107 patients. Based on these data, the 5-, 10-and 20-year overall survival are 55.0%, 43.5% and 15.7% respectively. The 5-, 10-, 20- year event-free survival rates are 45.0%, 27.2% and 8.1%, respectively. Treatment without surgery is associated with poorer overall survival and event-free survival. Negative surgical margins could significantly bring down the local-recurrence rate and are associated with a higher event-free survival rate. Chemotherapy regime based on anthracyclines does not benefit the overall survival. The addition of radiation therapy is not significantly associated with the overall or event-free survival. However, we recommend radiation as the salvage therapy for patients with positive margin so as to achieve better local control.
This review shows that surgery is essential in the management of MCS of bone and soft tissue. Appropriate adjuvant therapy may reduce local recurrence, but cannot benefit the overall survival.</description><subject>Analysis</subject><subject>Anthracycline</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>Bone Neoplasms - surgery</subject><subject>Bone surgery</subject><subject>Bone tumors</subject><subject>Cancer metastasis</subject><subject>Chemotherapy</subject><subject>Chondrosarcoma</subject><subject>Chondrosarcoma, Mesenchymal - drug therapy</subject><subject>Chondrosarcoma, Mesenchymal - radiotherapy</subject><subject>Chondrosarcoma, Mesenchymal - surgery</subject><subject>Humans</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>Patients</subject><subject>Quality</subject><subject>Radiation</subject><subject>Radiation (Physics)</subject><subject>Radiation therapy</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Salvage</subject><subject>Soft Tissue Neoplasms - drug therapy</subject><subject>Soft Tissue Neoplasms - radiotherapy</subject><subject>Soft Tissue Neoplasms - surgery</subject><subject>Stem cells</subject><subject>Surgery</subject><subject>Survival</subject><subject>Treatment Outcome</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk0tv1DAQxyMEoqXwDRBYQkJw2MWvxAkHpKrisVJRJV5Xy7HHu1kl8dZ2Cvvt8e6m1Qb1gHywPf7NfzxjT5Y9J3hOmCDv1m7wvWrnG9fDHBNKKSkeZKekYnRWUMweHq1PsichrDHOWVkUj7MTmpe8orQ4zdqvEKDXq22nWqRXrjfeBeW16xRyFtVJHKneoOBsRLEJYYD3SKGwDRE6FRuNPNw08HsHEyzQJtmgjwE1PYorSPsQEcVoC8qHp9kjq9oAz8b5LPv56eOPiy-zy6vPi4vzy5kWeRlnRWU00cyUhc4LsKwktraEMmtIUXEQNNcMhGGYccE1NVRwQSpdl5aXJWfAzrKXB91N64IcCxUkKQTBhBPOErE4EMaptdz4plN-K51q5N7g_FIqn7JrQRLCRcFqZgEUN6pU1NamqC22xBiBq6T1YYw21B0YndL3qp2ITk_6ZiWX7kZyVpa5oEngzSjg3fUAIcquCRraVvXghv29Ka4I3sd69Q96f3YjtVQpgaa3LsXVO1F5zmklRJkTnKj5PVQaBrpGp4e3TbJPHN5OHBIT4U9cqiEEufj-7f_Zq19T9vURuwLVxlVw7RAb14cpyA-gTp80eLB3RSZY7prithpy1xRybIrk9uL4ge6cbruA_QVaFAaE</recordid><startdate>20150407</startdate><enddate>20150407</enddate><creator>Xu, Jie</creator><creator>Li, Dasen</creator><creator>Xie, Lu</creator><creator>Tang, Shun</creator><creator>Guo, Wei</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150407</creationdate><title>Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years</title><author>Xu, Jie ; Li, Dasen ; Xie, Lu ; Tang, Shun ; Guo, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-69dc1c3d86c56ef381fbf123fd1694e725c3e7d303474c2d274719cb8f48843e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Anthracycline</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>Bone Neoplasms - surgery</topic><topic>Bone surgery</topic><topic>Bone tumors</topic><topic>Cancer metastasis</topic><topic>Chemotherapy</topic><topic>Chondrosarcoma</topic><topic>Chondrosarcoma, Mesenchymal - drug therapy</topic><topic>Chondrosarcoma, Mesenchymal - radiotherapy</topic><topic>Chondrosarcoma, Mesenchymal - surgery</topic><topic>Humans</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>Patients</topic><topic>Quality</topic><topic>Radiation</topic><topic>Radiation (Physics)</topic><topic>Radiation therapy</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Salvage</topic><topic>Soft Tissue Neoplasms - drug therapy</topic><topic>Soft Tissue Neoplasms - radiotherapy</topic><topic>Soft Tissue Neoplasms - surgery</topic><topic>Stem cells</topic><topic>Surgery</topic><topic>Survival</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Jie</creatorcontrib><creatorcontrib>Li, Dasen</creatorcontrib><creatorcontrib>Xie, Lu</creatorcontrib><creatorcontrib>Tang, Shun</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Jie</au><au>Li, Dasen</au><au>Xie, Lu</au><au>Tang, Shun</au><au>Guo, Wei</au><au>Loeb, David M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-04-07</date><risdate>2015</risdate><volume>10</volume><issue>4</issue><spage>e0122216</spage><epage>e0122216</epage><pages>e0122216-e0122216</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Mesenchymal chondrosarcoma(MCS) is a rare high-grade variant of chondrosarcoma. Consensus has not been reached on its optimal management. Resection with wide margins is usually recommended, but the effect of margins has been demonstrated by little positive evidence. Moreover, the effectiveness of adjuvant chemo- and/or radiotherapy remains controversial.
To describe the clinical characteristics and outcomes of MCS of bone and soft tissue, to assess the efficacies of surgery, chemotherapy and radiation, and finally to deliver a more appropriate therapy.
We reviewed EMBASE-, MEDLINE-, Cochrane-, Ovid- and PubMed-based to find out all cases of MCS of bone and soft tissue described between April 1994 and April 2014. Description of treatment and regular follow-up was required for each study. Language was restricted to English and Chinese. Issues of age, gender, location, metastasis, and treatment were all evaluated for each case. Kaplan-Meier Method and Cox Proportional Hazard Regression Model were used in the survival analysis.
From the 630 identified publications, 18 meeting the inclusion criteria were selected, involving a total of 107 patients. Based on these data, the 5-, 10-and 20-year overall survival are 55.0%, 43.5% and 15.7% respectively. The 5-, 10-, 20- year event-free survival rates are 45.0%, 27.2% and 8.1%, respectively. Treatment without surgery is associated with poorer overall survival and event-free survival. Negative surgical margins could significantly bring down the local-recurrence rate and are associated with a higher event-free survival rate. Chemotherapy regime based on anthracyclines does not benefit the overall survival. The addition of radiation therapy is not significantly associated with the overall or event-free survival. However, we recommend radiation as the salvage therapy for patients with positive margin so as to achieve better local control.
This review shows that surgery is essential in the management of MCS of bone and soft tissue. Appropriate adjuvant therapy may reduce local recurrence, but cannot benefit the overall survival.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25849226</pmid><doi>10.1371/journal.pone.0122216</doi><tpages>e0122216</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-04, Vol.10 (4), p.e0122216-e0122216 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1671014143 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Analysis Anthracycline Bone cancer Bone Neoplasms - drug therapy Bone Neoplasms - radiotherapy Bone Neoplasms - surgery Bone surgery Bone tumors Cancer metastasis Chemotherapy Chondrosarcoma Chondrosarcoma, Mesenchymal - drug therapy Chondrosarcoma, Mesenchymal - radiotherapy Chondrosarcoma, Mesenchymal - surgery Humans Mesenchyme Metastases Patients Quality Radiation Radiation (Physics) Radiation therapy Regression analysis Regression models Salvage Soft Tissue Neoplasms - drug therapy Soft Tissue Neoplasms - radiotherapy Soft Tissue Neoplasms - surgery Stem cells Surgery Survival Treatment Outcome |
| title | Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A56%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mesenchymal%20chondrosarcoma%20of%20bone%20and%20soft%20tissue:%20a%20systematic%20review%20of%20107%20patients%20in%20the%20past%2020%20years&rft.jtitle=PloS%20one&rft.au=Xu,%20Jie&rft.date=2015-04-07&rft.volume=10&rft.issue=4&rft.spage=e0122216&rft.epage=e0122216&rft.pages=e0122216-e0122216&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0122216&rft_dat=%3Cgale_plos_%3EA429778510%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1671014143&rft_id=info:pmid/25849226&rft_galeid=A429778510&rft_doaj_id=oai_doaj_org_article_114763b3feea4da8a2fbd6bf0f1dd709&rfr_iscdi=true |